High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 5.1% in the afternoon session after the stock's positive momentum was extended as the company, along with partner Merck, presented positive long-term data for its personalized mRNA-based cancer vaccine.
Biopharma M&A has surged to $106 billion across 201 deals through early June 2026, putting the sector on track for its strongest full-year total since the 2019 pre-pandemic peak, CNBC reported.
Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index climbing 3.2%
In the last week, the United States market has stayed flat, yet it is up 26% over the past year with earnings forecast to grow by 17% annually. In such a robust market environment, identifying stocks trading below their intrinsic value can present unique opportunities for investors seeking potential growth.
Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therapies, with potential milestones nearing $4 billion.
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Sanofi shares slip despite strong growth. However, Dupixent, new launches, pipeline progress and a low valuation support staying invested.
US stocks were expected to head in different directions on Thursday morning, as oil prices retreat but tech earnings overnight disappointed investors. Dow Jones futures were called 0.8% higher, but the S&P 500 was off 0.4% and Nasdaq futures were down 1.3%. The latter pair were...
The United States market remained flat over the last week but has seen a 26% increase over the past year, with earnings forecast to grow by 17% annually. In such a market environment, identifying stocks that are trading below their fair value can offer potential opportunities for investors seeking to capitalize on future growth prospects.
Major stock indexes finished mostly higher Thursday, even though Broadcom and other AI chipmaker stocks sank.
FTSE 100 up 8 points to 10,341 Oil prices soften on Israel-Lebanon ceasefire CMC Markets nears five-year high on results 2.56pm: Toddlers' picnic on Wall Street As expected, Wall Street has opened like a toddlers' picnic, with everyone heading off in different...
Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks With Remarkable Resilience. Moderna snapped a four-day losing streak on Wednesday, jumping 7.49 percent to finish at $49.06 apiece, as investors positioned portfolios ahead of its participation in a conference next week. In a notice to investors, Moderna Inc. (NASDAQ:MRNA) said that it is set to […]
Erasca Inc. (NASDAQ:ERAS) is one of the best growth stocks under $20 to buy. On May 11, Erasca reported positive progress for its precision oncology pipeline, highlighting monotherapy efficacy and a favorable safety profile for its lead candidate, ERAS-0015, in KRAS G12X lung and pancreatic cancers. The company is accelerating development, having already initiated monotherapy […]
Over the last 7 days, the United States market has risen by 1.2%, contributing to a significant 27% increase over the past year, with earnings expected to grow by 17% annually. In this thriving environment, identifying stocks that are potentially trading below their estimated value can offer investors opportunities for growth and diversification.
Analysts have been nudging Merck price targets higher, with some moves running from US$135 to US$150, while the core fair value model remains anchored at US$129.74 per share. These target changes are closely tied to how researchers view the potential of pipeline assets like Sac TMT and TERN-701, alongside the risks around trial outcomes and deal terms. As you read on, you will see how to track these shifting views and what they might mean for your own Merck thesis over time. Stay updated as...
GSK's Specialty Medicines business is the company's primary growth driver, supported by HIV leadership, new drug launches and a deep late-stage pipeline.
AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.
Pfizer (NYSE:PFE) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly. Pfizer wrapped fiscal 2025 with a $0.66 adjusted EPS Q4 beat. Merck followed with a Q1 2026 report dominated by a $9 billion Cidara acquisition charge. Two very different income stories for yield hunters. One Pays You to ... Pfizer vs Merck: Chasing High Yield vs Higher Returns
The United States market has shown robust performance recently, climbing 1.2% in the last week and rising an impressive 27% over the past year, with earnings expected to grow by 17% annually. In this environment, identifying stocks that may be priced below their estimated worth can offer potential opportunities for investors seeking value amidst overall market growth.
As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.
The United States market has shown impressive performance, rising 1.6% over the last week and climbing 28% in the past year, with earnings forecasted to grow by 17% annually. In light of these conditions, identifying stocks that may be priced below their estimated value can offer opportunities for investors seeking potential growth at a reasonable cost.
Merck & Co., Inc. (NYSE:MRK) is one of the best inexpensive stocks to invest in right now. Merck & Co., Inc. (NYSE:MRK) announced on May 26 that its Board of Directors declared a quarterly dividend of $0.85 per share of the company’s common stock for fiscal Q3 2026, with payments set to be made on July […]
PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.
Over the last 7 days, the United States market has risen 1.6%, contributing to a 28% increase over the past year, with earnings anticipated to grow by 17% annually in the coming years. In this context of robust market performance, identifying stocks that are trading below their intrinsic value can offer investors potential opportunities for growth and value appreciation.
Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]
Merck & Co., Inc. (NYSE:MRK) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week. It was one of the stocks mentioned in Cramer’s game plan, as he remarked: Now Merck… Monday evening, very odd… the actual 6:00 PM, hosts a meeting to review its […]
The United States market has shown robust performance, rising 1.6% over the last week and surging 28% over the past year, with earnings forecasted to grow by 17% annually. In this environment, identifying stocks trading at significant discounts can offer potential opportunities for investors looking to capitalize on undervaluation relative to market growth expectations.
MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
